OpenAI Group PBC buys Orchestra Bio for drug development agents

OpenAI's case for the deal centers on how long drug development takes: getting a new medicine through to U.S. regulatory approval takes 10 to 15 years on average by the company's count, and programs pass between departments and outside partners whose systems often do not connect. Orchestra's agents are meant to take over monitoring of studies, tracking finances and sorting out clinical trial scheduling problems. In OpenAI's telling, a failed manufacturing batch that threatens to push a trial back would set the software to work out which activities and timelines are hit and weigh ways to respond, though people still make the final call.

The Rosalind business that Orchestra is joining dates to April, when GPT-Rosalind launched as a reasoning model for biology and drug discovery research. Eligible organizations have been able to use it outside research preview since September under a trusted-access program, and Rosalind Workbench connects the model to scientific tools and data. Novo Nordisk A/S and Moderna Inc. are among the drugmakers already working with OpenAI on Rosalind, with the Danish company seeking faster research and commercial execution and Moderna's scientists using the models to turn complex data into plans for experiments.

The deal is not OpenAI's first in health care this year. Medical records company Torch Health Inc. joined OpenAI in January to build out ChatGPT Health, and about $400 million changed hands in April when rival Anthropic PBC bought AI biotech startup Coefficient Bio. Orchestra Bio itself is a venture capital-backed startup that Chief Executive Ashoka Rajendra founded in San Francisco in 2022, with backing at its August 2025 launch coming to $20 million from investors including Andreessen Horowitz, 8VC and Insight Venture Management.